CytomX Therapeutics Inc. (NASDAQ:CTMX) Director Ix L.P. Canaan sold 42,550 shares of CytomX Therapeutics stock in a transaction that occurred on Tuesday, November 22nd. The stock was sold at an average price of $11.71, for a total transaction of $498,260.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ix L.P. Canaan also recently made the following trade(s):

  • On Monday, November 21st, Ix L.P. Canaan sold 45,324 shares of CytomX Therapeutics stock. The stock was sold at an average price of $11.61, for a total transaction of $526,211.64.
  • On Wednesday, November 16th, Ix L.P. Canaan sold 51,581 shares of CytomX Therapeutics stock. The stock was sold at an average price of $11.50, for a total transaction of $593,181.50.
  • On Monday, November 14th, Ix L.P. Canaan sold 86,270 shares of CytomX Therapeutics stock. The stock was sold at an average price of $11.16, for a total transaction of $962,773.20.
  • On Wednesday, November 9th, Ix L.P. Canaan sold 13,730 shares of CytomX Therapeutics stock. The stock was sold at an average price of $11.03, for a total transaction of $151,441.90.

Shares of CytomX Therapeutics Inc. (NASDAQ:CTMX) opened at 12.03 on Thursday. The company’s market cap is $437.92 million. The firm’s 50-day moving average is $12.33 and its 200-day moving average is $11.69. CytomX Therapeutics Inc. has a one year low of $9.10 and a one year high of $24.68.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Large investors have recently modified their holdings of the company. SG Americas Securities LLC bought a new stake in shares of CytomX Therapeutics during the third quarter valued at about $117,000. American International Group Inc. boosted its stake in shares of CytomX Therapeutics by 165.7% in the second quarter. American International Group Inc. now owns 11,759 shares of the company’s stock valued at $120,000 after buying an additional 7,333 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of CytomX Therapeutics by 253.6% in the third quarter. Wells Fargo & Company MN now owns 7,808 shares of the company’s stock valued at $122,000 after buying an additional 5,600 shares in the last quarter. Nationwide Fund Advisors boosted its stake in shares of CytomX Therapeutics by 146.8% in the second quarter. Nationwide Fund Advisors now owns 12,925 shares of the company’s stock valued at $132,000 after buying an additional 7,688 shares in the last quarter. Finally, BlackRock Inc. boosted its stake in shares of CytomX Therapeutics by 23.2% in the third quarter. BlackRock Inc. now owns 9,344 shares of the company’s stock valued at $146,000 after buying an additional 1,759 shares in the last quarter. Institutional investors own 52.06% of the company’s stock.

Separately, Zacks Investment Research cut shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 11th.

ILLEGAL ACTIVITY WARNING: This news story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. and international copyright law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2016/11/24/ix-l-p-canaan-sells-42550-shares-of-cytomx-therapeutics-inc-ctmx-stock.html.

About CytomX Therapeutics

CytomX Therapeutics, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets.

5 Day Chart for NASDAQ:CTMX

Receive News & Stock Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related stocks with our FREE daily email newsletter.